July 15, 2020
Terumo Acquires Quirem Medical
July 15, 2020—Terumo Corporation announced it has completed the acquisition of Quirem Medical BV, a Netherlands-based health care startup specializing in next-generation microspheres for selective internal radiation therapy (SIRT) based on the radioactive isotope Holmium-166 to treat liver tumors. Quirem Medical is now a wholly-owned subsidiary of Terumo.
Under the terms of the agreement, Terumo acquired 80.1% of the shares of Quirem Medical. Terumo will make a one-time, up-front payment of $20 million with up to $25 million additional payments based on the achievement of future milestones by 2030. Terumo invested in Quirem Medical in 2015 and became the exclusive global distributor of the company's technology. Previously, Terumo held 19.9% of the company's shares.
According to Terumo, Quirem Medical's full Holmium SIRT platform includes QuiremSpheres, QuiremScout, and Q-Suite.
- QuiremSpheres are commercially available microspheres containing Holmium-166. Recent trials have shown the safety and efficacy of Holmium microspheres for the treatment of unresectable liver cancer. QuiremSpheres can be visualized and quantified in low concentrations by means of single-photon emission CT (SPECT) and MRI to improve patient selection, therapy planning, and treatment verification.
- QuiremScout is a low-dose Holmium microsphere that helps evaluate the biodistribution of microspheres before therapy.
- Q-Suite is a dosimetry software package used to plan QuiremSpheres treatments based on QuiremScout dose imaging. Q-Suite is also able to determine SIRT success immediately after the procedure by converting SPECT imaging and MRI into absorbed dose distributions.
The three products have received CE Mark approval and are available in Europe, the Middle East, and Africa. In the coming years, Terumo intends to launch the Holmium platform globally as part of the ongoing expansion of its interventional oncology portfolio.